<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03649022</url>
  </required_header>
  <id_info>
    <org_study_id>OSR-ARITM-001</org_study_id>
    <nct_id>NCT03649022</nct_id>
  </id_info>
  <brief_title>&quot;Ventricular Tachycardia Ablation Registry&quot;.</brief_title>
  <official_title>&quot;Ventricular Tachycardia Ablation Registry&quot;. Italian Registry of Substrate Mapping and VT Ablation With the Precision Mapping System and Flexability Catheter.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paolo Della Bella</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Catheter ablation of Ventricular Tachycardias is a well-established approach in clinical
      practice in patients with Implantable Cardioverter Defibrillator (ICD) implanted. Previous
      studies have shown a significant reduction in appropriate shocks (~ 20%) and a significant
      reduction in hospitalizations for cardiovascular reasons (~ 12%) in patients with ischemic
      heart disease treated with ablation. Recent works have also shown the effectiveness of the
      ablation procedure using as procedural target the reduction of late potentials. However,
      actually it is necessary to have an homogenize and accepted mapping scheme in Sinus Rhythm to
      ablate Ventricular Tachycardias related to scar substrate in patients with:

        -  Previous MI

        -  Previous myocarditis

        -  Arrhythmogenic Right Ventricular Dysplasia (ARVD)

        -  Idiopathic Dilated Cardiomyopathy (IDCM)

      Scope of the registry is to collect data during cardiac mapping in Sinus Rhythm in patients
      indicated for Ventricular Tachycardia ablation, that will be performed per clinical practice,
      by using the St. Jude Medical EnSiteTM PrecisionTM mapping system.

      The objective of the present registry is: to assess the acute and long-term efficacy of the
      strategy of substrate abolition (abolishment of complex and late potentials) guided by
      electroanatomic mapping with Precision software.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an Italian multicenter, observational, prospective and retrospective registry.

      Data will be collected during enrollment/baseline, procedure, pre-discharge and during the
      follow-up visits according to the standard practice of participating centers, with mandatory
      visits at 6 and 12 months. Data can also be collected retrospectively, prior informed consent
      of the patient.

      The planned enrollment duration is approximately 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 25, 2017</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Late potential abolition and ventricular tachycardia noninducibility</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>Combined procedural endpoint of late potential (LP) abolition and VT noninducibility (endpoint expected in 50% of cases).
LP abolition assessed as % of persistent LP area at remap after ablation, compared to the basal activation map.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventricular tachycardia recurrence</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from Ventricular Tachycardia episodes requiring ICD Intervention (shock or Anti-Tachycardia Pacing)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>During hospitalization: starting during the procedure until discharge</time_frame>
    <description>Periprocedural complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>12 months</time_frame>
    <description>Long term catheter ablation complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural parameters</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>Procedure duration measured in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural parameters</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>Fluoroscopy exposure measured in Gycm2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of cardiac mapping system EnSite Precision™ software (St.Jude, now Abbott)</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>Geometry precision, descriptive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of cardiac mapping system EnSite Precision™ software (St.Jude, now Abbott)</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>Mapping accuracy, descriptive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of cardiac mapping system EnSite Precision™ software (St.Jude, now Abbott)</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>System overall stability, descriptive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of cardiac mapping system EnSite Precision™ software (St.Jude, now Abbott)</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>Non-recoverable shifts/drifts, descriptive</description>
  </secondary_outcome>
  <enrollment type="Actual">312</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Catheter ablation</intervention_name>
    <description>Ventricular Tachycardia ablation, that will be performed per clinical practice, by using EnSite Precision mapping system with the Flexability catheter (St.Jude, now Abbott)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Population of patients with defibrillator, indicated to perform catheter ablation of
        ventricular tachycardia related to substrate scar due to previous MI, previous myocarditis
        and arrhythmogenic right ventricular dysplasia, idiopathic dilated cardiomyopathy guided by
        electroanatomic mapping system.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with an implanted ICD

          -  Patients with indication to Ventricular Tachycardia Ablation procedure, supported by
             EnSite Precision 3D mapping system (previous MI, myocarditis, ARVD, IDCM)

          -  Age 18 years or more

          -  Able to provide an informed consent to participate to the registry and available to
             respect the assessments described in the protocol

        Exclusion Criteria:

          -  Contraindication to anticoagulants

          -  Presence of thrombi

          -  Presence of Mitral and Aortic prosthetic valve

          -  Recent (&lt;3 months) myocardial infarction or unstable angina or Coronary Artery Bypass

          -  Pregnant or nursing

          -  Ventricular Tachycardia caused by reversible pathology

          -  &lt; 1 Year life expectancy according to the investigator

          -  Contraindication to the use of ablation/diagnostic catheters or to cardiac catheterism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Della Bella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS S Raffaele</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Reddy VY, Reynolds MR, Neuzil P, Richardson AW, Taborsky M, Jongnarangsin K, Kralovec S, Sediva L, Ruskin JN, Josephson ME. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007 Dec 27;357(26):2657-65.</citation>
    <PMID>18160685</PMID>
  </reference>
  <reference>
    <citation>Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekvål TM, Spaulding C, Van Veldhuisen DJ; ESC Scientific Document Group . 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015 Nov 1;36(41):2793-2867. doi: 10.1093/eurheartj/ehv316. Epub 2015 Aug 29.</citation>
    <PMID>26320108</PMID>
  </reference>
  <reference>
    <citation>Silberbauer J, Oloriz T, Maccabelli G, Tsiachris D, Baratto F, Vergara P, Mizuno H, Bisceglia C, Marzi A, Sora N, Guarracini F, Radinovic A, Cireddu M, Sala S, Gulletta S, Paglino G, Mazzone P, Trevisi N, Della Bella P. Noninducibility and late potential abolition: a novel combined prognostic procedural end point for catheter ablation of postinfarction ventricular tachycardia. Circ Arrhythm Electrophysiol. 2014 Jun;7(3):424-35. doi: 10.1161/CIRCEP.113.001239. Epub 2014 May 15.</citation>
    <PMID>24833642</PMID>
  </reference>
  <reference>
    <citation>Deo R, Albert CM. Epidemiology and genetics of sudden cardiac death. Circulation. 2012 Jan 31;125(4):620-37. doi: 10.1161/CIRCULATIONAHA.111.023838.</citation>
    <PMID>22294707</PMID>
  </reference>
  <reference>
    <citation>Tung R, Boyle NG, Shivkumar K. Catheter ablation of ventricular tachycardia. Circulation. 2010 Jul 20;122(3):e389-91. doi: 10.1161/CIRCULATIONAHA.110.963371.</citation>
    <PMID>20644021</PMID>
  </reference>
  <reference>
    <citation>Aliot EM, Stevenson WG, Almendral-Garrote JM, Bogun F, Calkins CH, Delacretaz E, Bella PD, Hindricks G, Jaïs P, Josephson ME, Kautzner J, Kay GN, Kuck KH, Lerman BB, Marchlinski F, Reddy V, Schalij MJ, Schilling R, Soejima K, Wilber D; European Heart Rhythm Association; European Society of Cardiology; Heart Rhythm Society. EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Europace. 2009 Jun;11(6):771-817. doi: 10.1093/europace/eup098. Epub 2009 May 14.</citation>
    <PMID>19443434</PMID>
  </reference>
  <reference>
    <citation>Kuck KH, Schaumann A, Eckardt L, Willems S, Ventura R, Delacrétaz E, Pitschner HF, Kautzner J, Schumacher B, Hansen PS; VTACH study group. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet. 2010 Jan 2;375(9708):31-40. doi: 10.1016/S0140-6736(09)61755-4.</citation>
    <PMID>20109864</PMID>
  </reference>
  <reference>
    <citation>Themistoclakis S, Raviele A, China P, Pappone C, De Ponti R, Revishvili A, Aliot E, Kuck KH, Hoff PI, Shah D, Almendral J, Manolis AS, Chierchia GB, Oto A, Vatasescu RG, Sinkovec M, Cappato R; Atrial Fibrillation Survey Investigators. Prospective European survey on atrial fibrillation ablation: clinical characteristics of patients and ablation strategies used in different countries. J Cardiovasc Electrophysiol. 2014 Oct;25(10):1074-81. doi: 10.1111/jce.12462. Epub 2014 Jul 8.</citation>
    <PMID>24891043</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 8, 2018</study_first_submitted>
  <study_first_submitted_qc>August 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2018</study_first_posted>
  <last_update_submitted>April 12, 2020</last_update_submitted>
  <last_update_submitted_qc>April 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Paolo Della Bella</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

